David R Spigel Selected Research

Carboplatin (JM8)

1/2021	Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
12/2019	A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.
1/2018	nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2.
1/2018	Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2.
1/2018	Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
1/2018	Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC).
1/2018	Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.
9/2017	First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC).
1/2017	Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
1/2017	A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David R Spigel Research Topics

Disease

82	Neoplasms (Cancer) 11/2022 - 04/2002
71	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2022 - 01/2003
28	Disease Progression 01/2022 - 04/2002
24	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 08/2003
14	Neutropenia 01/2021 - 06/2008
13	Carcinoma (Carcinomatosis) 10/2022 - 11/2005
12	Thrombocytopenia (Thrombopenia) 01/2017 - 08/2008
11	Breast Neoplasms (Breast Cancer) 11/2021 - 04/2002
9	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2010
9	Fatigue 01/2020 - 12/2007
8	Diarrhea 12/2015 - 12/2007
7	Anemia 01/2021 - 01/2010
6	Melanoma (Melanoma, Malignant) 01/2021 - 09/2010
5	Brain Neoplasms (Brain Tumor) 01/2020 - 12/2009
5	Renal Cell Carcinoma (Grawitz Tumor) 10/2019 - 11/2005
5	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 07/2010
5	Exanthema (Rash) 09/2017 - 12/2007
5	Febrile Neutropenia 12/2014 - 11/2009
5	Hypersensitivity (Allergy) 10/2012 - 08/2007
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2022 - 05/2009
4	Body Weight (Weight, Body) 12/2018 - 06/2012
4	Neoplasm Metastasis (Metastasis) 12/2018 - 03/2006
4	Infections 01/2017 - 01/2012
4	Adenocarcinoma 04/2013 - 03/2006
4	Prostatic Neoplasms (Prostate Cancer) 06/2012 - 03/2006
3	Nausea 01/2020 - 11/2009
3	Vomiting 01/2020 - 11/2009
3	Head and Neck Neoplasms (Head and Neck Cancer) 01/2016 - 05/2009
3	Mucositis 02/2015 - 05/2009
2	Microsatellite Instability 01/2022 - 11/2021
2	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 01/2020
2	Proteinuria 01/2018 - 11/2011
2	Hemorrhage 01/2018 - 02/2015
2	Pneumonia (Pneumonitis) 01/2017 - 04/2012

Drug/Important Bio-Agent (IBA)

34	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 10/2005
25	Bevacizumab (Avastin)FDA Link 01/2018 - 11/2005
21	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 10/2005
19	Docetaxel (Taxotere)FDA Link 01/2021 - 03/2006
18	PlatinumIBA 10/2022 - 09/2007
16	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 11/2005
15	NivolumabIBA 10/2022 - 06/2015
14	Gemcitabine FDA Link 01/2017 - 11/2005
13	Pemetrexed (MTA)FDA Link 12/2019 - 01/2010
11	ErbB Receptors (EGF Receptor)IBA 01/2018 - 11/2005
10	Monoclonal AntibodiesIBA 01/2021 - 12/2011
9	Pharmaceutical PreparationsIBA 01/2020 - 11/2005
8	Trastuzumab (Herceptin)FDA Link 01/2021 - 04/2002
7	atezolizumabIBA 10/2022 - 01/2018
7	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 08/2003
6	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2017
6	IpilimumabIBA 10/2022 - 05/2013
6	LigandsIBA 01/2022 - 06/2012
6	B7-H1 AntigenIBA 01/2021 - 10/2018
6	Etoposide (VP 16)FDA LinkGeneric 01/2017 - 10/2005
6	Topotecan (Hycamtin)FDA LinkGeneric 12/2014 - 10/2005
5	Immune Checkpoint InhibitorsIBA 11/2022 - 06/2015
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 11/2005
4	Sorafenib (BAY 43-9006)FDA Link 11/2017 - 05/2010
4	Everolimus FDA Link 02/2015 - 05/2010
4	Cytotoxins (Cytolysins)IBA 10/2012 - 08/2006
4	Angiogenesis InhibitorsIBA 08/2012 - 01/2010
4	Hormones (Hormone)IBA 04/2011 - 03/2006
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2011 - 06/2008
4	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2011 - 06/2008
3	durvalumabIBA 01/2022 - 12/2018
3	pembrolizumabIBA 01/2022 - 10/2020
3	pertuzumabIBA 01/2021 - 01/2018
3	Immunoconjugates (Immunoconjugate)IBA 01/2020 - 01/2017
3	amrubicinIBA 01/2018 - 05/2010
3	CrizotinibIBA 01/2018 - 05/2014
3	onartuzumabIBA 02/2017 - 11/2012
3	AnthracyclinesIBA 12/2014 - 04/2002
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2013 - 09/2008
3	Cetuximab (Erbitux)FDA Link 07/2010 - 08/2007
3	Rituximab (Mabthera)FDA Link 02/2010 - 03/2008
3	Gefitinib (Iressa)FDA Link 01/2010 - 09/2005
3	Imatinib Mesylate (Gleevec)FDA Link 11/2009 - 09/2007
3	taxaneIBA 08/2009 - 08/2006
3	Vinorelbine (Navelbine)FDA LinkGeneric 08/2009 - 09/2007
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 12/2012
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2015
2	130-nm albumin-bound paclitaxelIBA 01/2021 - 01/2018
2	hydroxide ionIBA 01/2021 - 10/2020
2	ceritinibIBA 01/2020 - 01/2017
2	Epidermal Growth Factor (EGF)IBA 01/2018 - 05/2010
2	Anaplastic Lymphoma KinaseIBA 01/2018 - 01/2017
2	pazopanib FDA Link 01/2018 - 08/2012
2	necitumumabIBA 01/2018 - 01/2017
2	pegfilgrastim (Neulasta)FDA Link 01/2018 - 06/2008
2	Panitumumab (Vectibix)FDA Link 09/2017 - 01/2016

Therapy/Procedure

45	Therapeutics 10/2022 - 04/2002
39	Drug Therapy (Chemotherapy) 10/2022 - 04/2002
9	Radiotherapy 09/2017 - 12/2007
8	Immunotherapy 01/2022 - 09/2010
5	Chemoradiotherapy 01/2022 - 01/2010
4	Adjuvant Chemotherapy 11/2018 - 12/2007
4	Combination Drug Therapy (Combination Chemotherapy) 01/2018 - 11/2005
4	Combined Modality Therapy 04/2012 - 05/2009
2	Aftercare (After-Treatment) 02/2017 - 05/2010
2	Molecular Targeted Therapy 01/2017 - 04/2002